Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid Stoffw Microb

Gauckler, P; Regele, H; Eller, K; Säemann, MD; Lhotta, K; Zitt, E; Neumann, I; Rudnicki, M; Odler, B; Kronbichler, A; Windpessl, M.
[Diagnosis and treatment of Minimal Change Disease in adults-2023].
Wien Klin Wochenschr. 2023; 135(Suppl 5): 628-637. Doi: 10.1007/s00508-023-02258-5 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Co-Autor*innen der Med Uni Graz
Eller Kathrin
Odler Balazs
Altmetrics:

Dimensions Citations:

Plum Analytics:

Scite (citation analytics):

Abstract:
Minimal change disease is a glomerulopathy that clinically manifests as acute onset nephrotic syndrome. A diagnosis is made by renal biopsy, implying the absence of glomerular lesions on light microscopy but detection of extensive podocyte foot process effacement on electron miscroscopy. Considering the typically excellent response to immunosuppressive measures (especially to glucocorticoids), an autoimmune pathogenesis is assumed. Although general prognosis is overall beneficial, steroid-dependent, steroid-resistant and frequently-relapsing disease courses may complicate the management of these patients and necessitate the use of alternative immunosuppressive treatment strategies. Here, the Austrian Society of Nephrology (ÖGN) provides a consensus on how to best diagnose and manage adult patients with minimal change disease.
Find related publications in this database (using NLM MeSH Indexing)
Humans - administration & dosage
Adult - administration & dosage
Nephrosis, Lipoid - diagnosis, therapy
Austria - administration & dosage
Consensus - administration & dosage
Disease Progression - administration & dosage
Nephrology - administration & dosage
Nephrotic Syndrome - administration & dosage

Find related publications in this database (Keywords)
Minimal Change Disease
Podocytopathy
Glucocorticoids
© Med Uni Graz • Impressum